Anti-Human Amyloid-β (Aducanumab) - 50 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

Amyloid-β (Aβ) is a peptide that accumulates in the brains of individuals with Alzheimer’s disease, forming plaques that are a hallmark of the condition. These plaques are believed to contribute to theneurodegenerative processes seen in Alzheimer’s by disrupting cell function and triggeringinflammatory responses. Amyloid-β is derived from the amyloid precursor protein (APP) throughenzymatic cleavage. The aggregation of Aβ into oligomers and fibrils is a key pathological feature ofAlzheimer’s disease, making it a significant target for therapeutic interventions aimed at reducing orpreventing plaque formation 1, 21, 2. Aducanumab is a human monoclonal antibody of the IgG1 isotype that specifically targets aggregatedforms of amyloid-β. Developed by Biogen and Neurimmune, Aducanumab was designed to bind toamyloid plaques in the brain, facilitating their clearance by the immune system. Clinical studies haveshown that Aducanumab can reduce amyloid plaque levels in patients with early Alzheimer’s disease, potentially slowing cognitive decline. The development of Aducanumab involved identifyingantibodies from healthy elderly individuals who were cognitively normal, leveraging their immuneresponse to create a therapeutic antibody2-4.

≥ 5.0 mg/ml

Amyloid-β (Aβ) is primarily found in the brain, where it accumulates to formplaques in individuals with Alzheimer’s disease.